Pinealon Research Overview

Background and Classification

Pinealon belongs to the same family of bioregulatory tetrapeptides and tripeptides developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology that produced Epithalon (Ala-Glu-Asp-Gly) and Cortagen (Ala-Glu-Asp-Pro). Pinealon is distinguished by being the truncated three-amino-acid core — Ala-Glu-Asp — shared across the entire family, isolated as the minimal fragment retaining biological activity from pineal gland polypeptide extracts.

Because Pinealon represents the shared structural core of this peptide family without a tissue-specific C-terminal extension, research has proposed it may interact more broadly across the CNS rather than showing the same degree of tissue selectivity documented for Epithalon (pineal/telomerase-focused) or Cortagen (cortex-focused). Its small size — among the smallest research peptides in this category — also makes it an unusually practical candidate for intranasal administration research, a delivery route generally impractical for larger peptides.

• Sequence: Ala-Glu-Asp (AED)

• Molecular Weight: ~317 Da

• Source Tissue: Pineal gland (parent polypeptide extract)

• Core Sequence Shared With: Epithalon (AED-Gly); Cortagen (AED-Pro)

• Administration Routes: Subcutaneous, intranasal (research)

• Primary Research Focus: CNS neuroprotection, retinal health, circadian support

The Khavinson Bioregulatory Peptide Family

• Peptide: Epithalon — Sequence: Ala-Glu-Asp-Gly — Source Tissue: Pineal gland — Primary Research Target: Telomerase; systemic aging; longevity — Distinguishing Feature: Telomere elongation; broadest anti-aging evidence

• Peptide: Pinealon — Sequence: Ala-Glu-Asp — Source Tissue: Pineal gland — Primary Research Target: CNS/retinal neuroprotection; circadian — Distinguishing Feature: Smallest; intranasal CNS delivery potential

• Peptide: Cortagen — Sequence: Ala-Glu-Asp-Pro — Source Tissue: Cerebral cortex — Primary Research Target: Cortical neuroprotection; cognitive aging — Distinguishing Feature: Pro residue; cortex-targeted tissue selectivity

• Peptide: Vilon — Sequence: Lys-Glu — Source Tissue: Thymus/immune — Primary Research Target: Immune regulation; T-cell function — Distinguishing Feature: Dipeptide; immune tissue origin

• Peptide: Thymogen — Sequence: Glu-Trp — Source Tissue: Thymus — Primary Research Target: T-cell differentiation; IL-2 — Distinguishing Feature: Approved in Russia; longest clinical use

Mechanism of Action

Pinealon's proposed mechanism follows the same peptide-DNA interaction model advanced by Khavinson's group for the broader tetrapeptide bioregulator series: nuclear entry and modulation of chromatin structure at gene promoter regions relevant to neuronal survival and cellular protection. As the minimal AED core sequence, Pinealon is hypothesized to engage a broader, less tissue-restricted set of gene targets than its longer relatives, consistent with its documented effects across multiple CNS tissue types rather than a single structure.

Downstream effects documented in Pinealon research include upregulation of neurotrophic factors, reduction of pro-apoptotic signaling in stressed neurons, enhancement of endogenous antioxidant enzyme expression, and modulation of circadian gene expression — the latter consistent with its pineal-derived origin and the gland's central role in melatonin synthesis and circadian regulation.

As with other members of this peptide family, the peptide-DNA interaction model remains more hypothesis than confirmed mechanism. Independent mechanistic validation beyond Khavinson's group is limited, and the functional outcomes documented in animal models are better established than the proposed molecular basis for them.

Research Domains

CNS NeuroprotectionReduces neuronal apoptosis across multiple brain regions in oxidative stress and ischemia models. Broader anatomical effect profile than the more cortex-restricted Cortagen. Retinal ProtectionProtects retinal ganglion cells and photoreceptors in light-induced and inherited degeneration models. Frequently studied alongside Cortagen for complementary retinal research. Circadian ResearchPineal-derived origin connects Pinealon research to circadian rhythm and melatonin synthesis pathways, an area less explored in Cortagen or Epithalon research specifically. Cognitive FunctionImproves performance on spatial memory tasks in aged rodent models. Increases hippocampal neurotrophic factor expression alongside reduced neuroinflammatory markers. Intranasal Delivery ResearchSmall molecular size (~317 Da) makes Pinealon one of the few research peptides with documented intranasal CNS delivery studies, bypassing the blood-brain barrier limitations of larger compounds. Antioxidant DefenceUpregulates SOD and catalase activity in neural tissue. Reduces oxidative DNA damage markers in aged brain tissue studies, consistent with the broader tetrapeptide class profile.

Intranasal Delivery — A Distinguishing Research Avenue

Pinealon's minimal size relative to other research peptides has made it a specific subject of intranasal delivery research — a route generally impractical for larger peptide compounds due to poor mucosal absorption and degradation. Animal studies administering Pinealon intranasally report measurable CNS tissue distribution and biological effect, suggesting at least partial bypass of first-pass metabolism and more direct access to brain tissue compared to systemic subcutaneous administration. This remains an active area of research interest specifically because so few peptide compounds are viable candidates for this delivery route at all.

Retinal Research

Pinealon has been studied in combination with Cortagen for retinal protection, particularly in models of light-induced retinal damage and inherited photoreceptor degeneration. The proposed rationale is complementary mechanism: Cortagen addressing cortical-pattern gene regulatory programmes that extend into retinal neurons, and Pinealon contributing pineal-axis effects relevant to circadian photoreceptor regulation. Combined administration in these models has shown greater protective effect than either compound studied alone, though no formal head-to-head dose-ranging trial isolating each compound's independent contribution has been published.

Pinealon + Cortagen in Research Stacks > > Within the Khavinson bioregulatory peptide framework, Pinealon and Cortagen are commonly studied together as complementary CNS-protective compounds — Pinealon contributing broader, less tissue-restricted neuroprotective and circadian effects, and Cortagen contributing more targeted cortical gene expression normalization. Researchers exploring this pairing typically reference the same retinal degeneration and cognitive aging literature that originally proposed the combination.

Stability and Research Handling

As one of the smallest compounds in the research peptide class at approximately 317 Da, Pinealon is highly stable and straightforward to reconstitute. Excellent aqueous solubility, minimal mechanical degradation risk, and stability at −20°C for 24+ months in lyophilized form make handling considerations minimal. Reconstituted solutions remain stable at 2–8°C for several weeks in bacteriostatic water. Its small size is also what enables the intranasal research applications noted above — though formal pharmacokinetic comparisons between intranasal and subcutaneous routes remain limited in the published literature.

Research Use Only. Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Pinealon is not approved by the FDA or any Western regulatory agency for human therapeutic use. Evidence originates primarily from the St. Petersburg Institute of Bioregulation with limited independent replication. This content does not constitute medical advice. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Khavinson VKh, et al. "Peptide bioregulators of aging — new data." *Adv Gerontol*. 2011;24(3):400–408.

1. Khavinson V, et al. "Short peptides regulate gene expression in the brain." *Neuro Endocrinol Lett*. 2008;29(3):285–291.

1. Sibarov DA, et al. "Cytoprotective effects of epitalon and pinealon in the early postnatal rat brain." *Cell Mol Neurobiol*. 2009;29(6–7):825–831.

1. Khavinson VKh, Grigoriev EI. "Peptide regulation of brain functions." *Bull Exp Biol Med*. 2005;139(4):371–374.

1. Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." *Biogerontology*. 2010;11(2):139–149.

1. Khavinson VKh, et al. "Retinal effects of bioregulatory tetrapeptides in retinitis pigmentosa models." *Neuro Endocrinol Lett*. 2013;34(7):687–692.